ONC201

Chimerix Reports Fourth Quarter and Year End 2023 Financial Results and Provides Operational Update

Retrieved on: 
Thursday, February 29, 2024
ONC201, MD, ASCO, Growth, Neuro-Oncology (journal), Manuscript, HGG, Conference, Human, Society, Patient, Journal, Survival, JCO, Pharmaceutical industry

DURHAM, N.C., Feb. 29, 2024 (GLOBE NEWSWIRE) -- Chimerix (NASDAQ:CMRX), a biopharmaceutical company whose mission it is to develop medicines that meaningfully improve and extend the lives of patients facing deadly diseases, today reported financial results for the fourth quarter and full-year ended December 31, 2023 and provided an operational update.

Key Points: 
  • ET Today –
    DURHAM, N.C., Feb. 29, 2024 (GLOBE NEWSWIRE) -- Chimerix (NASDAQ:CMRX), a biopharmaceutical company whose mission it is to develop medicines that meaningfully improve and extend the lives of patients facing deadly diseases, today reported financial results for the fourth quarter and full-year ended December 31, 2023 and provided an operational update.
  • Chimerix reported a net loss of $18.2 million, or $0.20 per basic and diluted share, for the fourth quarter of 2023, compared to a net loss of $21.0 million, or $0.24 per basic and diluted share for the fourth quarter of 2022.
  • General and administrative expenses decreased to $5.2 million for the fourth quarter of 2023, compared to $5.3 million for the same period in 2022.
  • Chimerix will host a conference call and live audio webcast to discuss fourth quarter and full-year 2023 financial results and provide a business update today at 8:30 a.m.

Chimerix Reports Inducement Grant Under Nasdaq Listing Rule 5635(c)(4)

Retrieved on: 
Friday, November 24, 2023
Patient, Compensated emancipation, Employment, ONC201

The Compensation Committee of Chimerix’s Board of Directors approved the award as an inducement material to the new employee’s employment agreement in accordance with Nasdaq Listing rule 5635(c)(4).

Key Points: 
  • The Compensation Committee of Chimerix’s Board of Directors approved the award as an inducement material to the new employee’s employment agreement in accordance with Nasdaq Listing rule 5635(c)(4).
  • The stock option has an exercise price per share equal to $1.00 per share, Chimerix’s closing trading price on November 20, 2023.
  • The stock option is subject to the terms of Chimerix’s 2013 Equity Incentive Plan but was granted outside of the 2013 Equity Incentive Plan.
  • Chimerix is a biopharmaceutical company with a mission to develop medicines that meaningfully improve and extend the lives of patients facing deadly diseases.

Chimerix Strengthens Executive Leadership Team with Appointment of Thomas Riga as Chief Operating and Commercial Officer

Retrieved on: 
Thursday, November 16, 2023
Acquisition, St. Lawrence University, Patient, Chief commercial officer, Eli Lilly and Company, Spectrum Pharmaceuticals, ONC201, Dendreon, Brain, Amgen, Management, Chemistry, Spectrum, Biology

DURHAM, N.C., Nov. 16, 2023 (GLOBE NEWSWIRE) -- Chimerix (NASDAQ:CMRX), a biopharmaceutical company whose mission is to develop medicines that meaningfully improve and extend the lives of patients facing deadly diseases, today announced the appointment of Thomas Riga as Chief Operating and Commercial Officer.

Key Points: 
  • DURHAM, N.C., Nov. 16, 2023 (GLOBE NEWSWIRE) -- Chimerix (NASDAQ:CMRX), a biopharmaceutical company whose mission is to develop medicines that meaningfully improve and extend the lives of patients facing deadly diseases, today announced the appointment of Thomas Riga as Chief Operating and Commercial Officer.
  • “We are excited to welcome Tom to the Chimerix team as his leadership and extensive market knowledge will be a great asset as we advance ONC201 toward commercialization,” said Mike Andriole, Chief Executive Officer of Chimerix.
  • “Tom’s in-depth oncology experience in commercial launch readiness, brand marketing, market access, and reimbursement will accelerate our readiness efforts with ONC201.
  • Prior to being named CEO of Spectrum, Mr. Riga served as the Chief Commercial Officer for nine years and Chief Operating Officer for five years.

KAZIA PROVIDES OVERVIEW OF PAXALISIB RELATED PRESENTATIONS FROM THE SOCIETY OF NEURO-ONCOLOGY 2023 ANNUAL MEETING

Retrieved on: 
Tuesday, November 21, 2023
CNS, DNA, Neoplasm, Metformin, PIK3CA, PI3K, Patient, KZIA, Radiation, Standard of care, MD, Diagnosis, DMG, Survival, ONC201, Female, DIPG, Society, DMG interpersonal, Pharmaceutical industry, Medical imaging

SYDNEY, Nov. 21, 2023 /PRNewswire/ -- Kazia Therapeutics Limited (NASDAQ: KZIA), an oncology-focused drug development company, is pleased to provide key highlights of the clinical and preclinical paxalisib related presentations given by key thought leaders at the Society of Neuro-Oncology 2023 Annual Meeting.

Key Points: 
  • SYDNEY, Nov. 21, 2023 /PRNewswire/ -- Kazia Therapeutics Limited (NASDAQ: KZIA), an oncology-focused drug development company, is pleased to provide key highlights of the clinical and preclinical paxalisib related presentations given by key thought leaders at the Society of Neuro-Oncology 2023 Annual Meeting.
  • "The 2023 SNO Annual Meeting was another successful event with the latest advances in clinical trials, diagnosis and treatment of pediatric and adult patients with CNS malignancies," stated Dr. John Friend, CEO Kazia.
  • "We are highly encouraged with the preliminary overall survival data from the PNOC022 clinical study that we believe will provide an alternative to the current therapies considered as standard of care."
  • Key paxalisib highlights from the meeting:
    Specifically, the authors observed how ONC201 over activates the PI3K-AKT pathway, which is the target pathway for paxalisib
    Two patient case studies were discussed; each receiving the combination of paxalisib and ONC201 through compassionate access
    Six-year old female with DIPG who received the combination of paxalisib and ONC201 after upfront radiation therapy.

KAZIA ANNOUNCES THE RELEASE OF PNOC022 CLINICAL STUDY ABSTRACT HIGHLIGHTING PAXALISIB IN DIFFUSE MIDLINE GLIOMA PATIENTS AHEAD OF THE SOCIETY OF NEURO-ONCOLOGY 2023 ANNUAL MEETING

Retrieved on: 
Wednesday, November 15, 2023
DRD2, Annual general meeting, Therapy, Eosinophilia, Disulfiram-like drug, Lymphocyte, Patient, KZIA, PNOC, Colitis, Mucositis, MD, Trial of the century, Diagnosis, DMG, Hyperglycemia, ONC201, Physician, OS, Society, Hypokalemia, DMG interpersonal, Pharmaceutical industry

The preliminary results from a single cohort in this Pacific Pediatric Neuro-Oncology Consortium (PNOC) sponsored cooperative group clinical study will be presented on Sunday, 19 November 2023 in Vancouver, Canada.

Key Points: 
  • The preliminary results from a single cohort in this Pacific Pediatric Neuro-Oncology Consortium (PNOC) sponsored cooperative group clinical study will be presented on Sunday, 19 November 2023 in Vancouver, Canada.
  • Sixty-eight children and young adults with DMG who completed standard of care radiation treatment received paxalisib (an investigational PI3K-mTOR dual inhibitor) and ONC201 (an investigational dopamine receptor D2 (DRD2) and ClpP agonist).
  • The abstract reported that median overall survival (OS) from time of diagnosis was 16.5 months.
  • "The PNOC022 study has exceeded expectations in terms of enrolment rates and has partnered with 29 leading children's cancer centers and physicians across the globe."

Chimerix Reports Third Quarter 2023 Financial Results and Provides Operational Update

Retrieved on: 
Thursday, November 2, 2023
Neoplasm, Survival, Action, Biomarker, Neuro, MOS, DMG, SNO, Conference, CNS, Central nervous system, ONC201, Annual general meeting, ACTION, European Association for the Study of the Liver, Pakistan Society of Neuro-Oncology, Cancer Discovery (journal), Patient, Human, Completeness, Pharmaceutical industry

DURHAM, N.C., Nov. 02, 2023 (GLOBE NEWSWIRE) -- Chimerix (NASDAQ:CMRX), a biopharmaceutical company whose mission is to develop medicines that meaningfully improve and extend the lives of patients facing deadly diseases, today reported financial results for the third quarter ended September 30, 2023 and provided an operational update.

Key Points: 
  • ET Today –
    DURHAM, N.C., Nov. 02, 2023 (GLOBE NEWSWIRE) -- Chimerix (NASDAQ:CMRX), a biopharmaceutical company whose mission is to develop medicines that meaningfully improve and extend the lives of patients facing deadly diseases, today reported financial results for the third quarter ended September 30, 2023 and provided an operational update.
  • Chimerix reported a net loss of $24.0 million, or $0.27 per basic and diluted share, for the third quarter of 2023.
  • Research and development expenses increased to $17.4 million for the third quarter of 2023, compared to $15.3 million for the same period in 2022.
  • Chimerix will host a conference call and live audio webcast to discuss third quarter 2023 financial results and provide a business update today at 8:30 a.m.

Chimerix Announces Data Highlighting Clinical Efficacy and Molecular Mechanisms of Response to ONC201 Treatment of H3 K27M-Mutant Diffuse Midline Gliomas Published in "Cancer Discovery"

Retrieved on: 
Wednesday, August 16, 2023
Glioma, ONC201, Cancer Discovery (journal), American Association for Cancer Research, Patient, Manuscript, Diagnosis, MOS, Versus, Pharmaceutical industry

DURHAM, N.C., Aug. 16, 2023 (GLOBE NEWSWIRE) -- Chimerix (NASDAQ:CMRX), a biopharmaceutical company whose mission it is to develop medicines that meaningfully improve and extend the lives of patients facing deadly diseases, today announced the publication of data in support of the Company’s first-in-class small molecule imipridone, ONC201, as a treatment for H3 K27M-mutant diffuse midline gliomas (H3K27M-DMG) in the peer-reviewed journal, Cancer Discovery, a journal of the American Association for Cancer Research.

Key Points: 
  • The manuscript titled, “Clinical efficacy of ONC201 in H3K27M-mutant diffuse midline gliomas is driven by disruption of integrated metabolic and epigenetic pathways,” reports survival analyses of 71 patients with H3 K27M-DMG treated with ONC201 which demonstrated promising results in a patient population with a poor prognosis and few treatment options.
  • These data are particularly relevant given that enrollment in the ongoing ACTION study occurs in a similar population.
  • Additionally, these data further elucidate the underlying novel mechanism of action for ONC201 in a patient population which has very limited treatment options,” said Mike Andriole, Chief Executive Officer of Chimerix.
  • “Prior to this study, there have been more than 250 clinical trials that have not been able to improve outcomes.

Chimerix Reports Second Quarter 2023 Financial Results and Provides Operational Update

Retrieved on: 
Thursday, August 3, 2023
Toxic leukoencephalopathy, Cancer, Neuro, Action, Patient, ACTION, Human, Reiterate, Conference, ONC201, Pharmaceutical industry

DURHAM, N.C., Aug. 03, 2023 (GLOBE NEWSWIRE) -- Chimerix (NASDAQ:CMRX), a biopharmaceutical company whose mission it is to develop medicines that meaningfully improve and extend the lives of patients facing deadly diseases, today reported financial results for the second quarter ended June 30, 2023 and provided an operational update.

Key Points: 
  • ET Today –
    DURHAM, N.C., Aug. 03, 2023 (GLOBE NEWSWIRE) -- Chimerix (NASDAQ:CMRX), a biopharmaceutical company whose mission it is to develop medicines that meaningfully improve and extend the lives of patients facing deadly diseases, today reported financial results for the second quarter ended June 30, 2023 and provided an operational update.
  • Chimerix reported a net loss of $18.6 million, or $0.21 per basic and diluted share, for the second quarter of 2023.
  • Research and development expenses decreased to $16.9 million for the second quarter of 2023, compared to $18.0 million for the same period in 2022.
  • Chimerix will host a conference call and live audio webcast to discuss second quarter 2023 financial results and provide a business update today at 8:30 a.m.

Chimerix Announces Promotion of Michael T. Andriole to President and Chief Executive Officer

Retrieved on: 
Tuesday, June 27, 2023
Lead, ONC201, Retirement, Patient, Chairperson, ACTION, Chair, Management

DURHAM, N.C., June 27, 2023 (GLOBE NEWSWIRE) -- Chimerix, Inc. (NASDAQ:CMRX), a biopharmaceutical company whose mission it is to develop medicines that meaningfully improve and extend the lives of patients facing deadly diseases, today announced the promotion of Mike Andriole, Chief Business Officer and Chief Financial Officer, to President and Chief Executive Officer of Chimerix and his appointment to the Board of Directors. Mr. Andriole replaces Mike Sherman, who is retiring from his role as Chief Executive Officer and will become Chairman of the Board of Directors. Martha Demski, the current Board Chair, will assume the role of Lead Independent Director. These appointments will be effective on August 1, 2023.

Key Points: 
  • DURHAM, N.C., June 27, 2023 (GLOBE NEWSWIRE) -- Chimerix, Inc. (NASDAQ:CMRX), a biopharmaceutical company whose mission it is to develop medicines that meaningfully improve and extend the lives of patients facing deadly diseases, today announced the promotion of Mike Andriole, Chief Business Officer and Chief Financial Officer, to President and Chief Executive Officer of Chimerix and his appointment to the Board of Directors.
  • Mr. Andriole replaces Mike Sherman, who is retiring from his role as Chief Executive Officer and will become Chairman of the Board of Directors.
  • Martha Demski, the current Board Chair, will assume the role of Lead Independent Director.
  • “The Board has been thoughtful in planning this succession, ensuring ongoing strong leadership with the continuity of an accomplished management team,” said Martha Demski, Board Chair of Chimerix.

KAZIA CEO, DR. JOHN FRIEND TO PARTICIPATE IN WHITE HOUSE CANCER MOONSHOT

Retrieved on: 
Thursday, May 25, 2023
White House, Disease, Radiation, Society, Drug development, GBM, Neuro-Oncology (journal), ONC201, Survival, American Association for Cancer Research, Research, Brain, Melanoma, Global Coalition Against Pneumonia, White, II, KZIA, DIPG, Patient, Cancer, Cancer Moonshot, Diagnosis, Diffuse intrinsic pontine glioma, PNOC, Oncology, FDA, Melanoma Research, Caregiver, Medical imaging, Glioblastoma, Kazia Pelka

SYDNEY, May 25, 2023 /PRNewswire/ -- Kazia Therapeutics Limited (NASDAQ: KZIA; ASX: KZA), an oncology-focused drug development company, has been invited to the White House to participate in the Cancer Moonshot Brain Cancers Forum on Glioblastoma (GBM) & Diffuse Intrinsic Pontine Glioma (DIPG), to be held on Thursday, 25 May 2023. 

Key Points: 
  • Kazia's CEO, Dr. John Friend, was invited and will be participating in this forum.
  • Friend to participate in the forum reflects the importance of Kazia's work in developing treatments for GBM and DIPG and reconfirms Kazia's position as a global leader in this field.
  • "We are honored to participate in the Cancer Moonshot forum on adult and pediatric brain cancer alongside global Neuro-Oncology thought leaders, researchers, US government officials and patient advocates," stated Dr.
  • GBM is the most aggressive and most common primary brain cancer with a five-year survival rate of approximately 10%.